BRAIN Biotech AG publishes 3-month report with optimism to remain on solid growth path
Parent company, BRAIN Biotech AG today published its first quarter results, 3M 2023/24, remaining optimistic to stay on the growth path for fiscal year 2023/24
Highlights from BRAIN Biotech AG's announcement:
- Strong BioScience business in Q1
- BioProducts growth to accelerate over the next quarters
- Optimistic outlook for the business year targeting revenue range of € 58 million to € 62 million
BRAIN Biotech Group generated Q1 revenue of € 12.7 million compared to € 13.7 million in the same period of the previous year, representing a decrease of 7.0 %. Total operating performance (revenue, research and development funding, changes in inventories and other income) decreased slightly by 3.1 % from € 13.5 million to € 13.1 million in the first three months of the financial year.
For full information on the BRAIN Biotech AG's financial figures for the first three months of the fiscal year 2023/24, click below.
“The BioProducts division has been faced by a very strong comparison quarter in the last year. We remain confident that our products segment will demonstrate increasingly dynamic growth over the next three quarters.
